The development of the daily daily retinal mono-antitherapy nAMD has achieved positive results.

2020.07.23 Research and Development NEWS: Junshi BioDAC-002 Injection scored by clinical trial approval notice; interval Asia-Sheng Pharmaceutical MDM2-p53 inhibitor China Phase 1b study completed the first patient administration; target FLT3! Repolar medicine in the research of new drugs in China to apply for breakthrough treatment drugs ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original text) (Drug Development) Treatment of nAMD Roche Rejure monoanti-glass implant 98% of patients to achieve the six-month delivery interval before the date, Roche announced the detailed results of the Phase III ARCHWAY trial.
418 patients with neonatal vascular (wet) age-related macular degeneration (nAMD) received at least three anti-VEGF injections in the six months prior to the study screening and were shown to be responsive to VEGF therapy.
Innovative Cell Therapy FCR001 completed the first live kidney transplant patient administration in Phase 3 clinical lying 22, Talaris Therapeutics corporation announced that it has completed the first live kidney transplant (LDKT) patient administration in a phase 3 clinical trial called FREEDOM-1 in cell therapy FCR001, which aims to evaluate the safety and effectiveness of THE FCR001 single administration.
AsiaSon Pharmaceuticals MDM2-p53 Inhibitors China Phase 1b Study Completed the first patient administration 22, AXA Pharmaceuticals announced that the company is working on a new class 1 new drug MDM2-p53 inhibitor APG-115 as a single drug and combined treatment of adult recurrence or difficult treatment of acute myeloid leukemia (AML), recurrence or progression of high-risk/extremely high-risk myelin hyperplasia syndrome (MDS) in China.
Fda Approves Innovative Narcolel Therapy For Marketing Jazz Pharmaceuticals today announced that the FDA approved the listing of Xywav (calcium, magnesium, potassium, and sodium hydroxybutyatis) oral solution on July 21, 2020 to treat dysnaral or daytime drowsiness in patients with narcolepsy 7 years and older.
target FLT3! Repole Pharma in the research of new drugs in China to apply for breakthrough treatment drugs 22, re-extreme medicine announced to NMPA application, identified in the research drug MAX-40279 for the treatment of FLT3 wild type of acute myeloid leukemia breakthrough treatment drugs.
Junshi BioDAC-002 Injection was approved by clinical trial notice 22, Junshi Biological issued a notice that the company's product SS108 (DAC-002) recently obtained the Approval of the State Drug Administration issued the "Drug Clinical Trial Approval Notice."
BoYu innovative freeze-dried human rabies vaccine with rabies vaccine approved drug clinical trial notice 23, Bo-Yu innovation announced that the company's holding sun company Zhongke Bio and Boottke signed a "project cooperation contract" in January 2020, jointly declared freeze-dried human rabies vaccine (no serum Vero cells) products.
the product was recently approved by the State Drug Administration to issue the "Drug Clinical Trial Approval Notice."
health yuan inhalation with budined mixed suspension will soon be listed on the 22nd, health yuan pharmaceutical industry's four generic drugs "inhalation with Budinaid mixed suspension" listing application in the approval state (CYHS1900132), is expected to be approved by the State Drug Administration, the second approved generic drug in the country.
.